Tag : TYROSINE

Latest News

New strategy identified to address the underlying cause of LAD1 patients' symptoms

Newsemia
Owing to a rare genetic mutation, individuals with leukocyte adhesion deficiency type 1 (LAD1) experience a suite of symptoms that trace back to an immune...
Latest News

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Newsemia
Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly...
Pharma / Biotech

Safety, Pharmacokinetics and Pharmacodynamics of Branebrutinib (BMS-986195), a Covalent, Irreversible Inhibitor of Bruton's Tyrosine Kinase: Randomised Phase I, Placebo-Controlled Trial in Healthy Participants.

Newsemia
Safety, Pharmacokinetics and Pharmacodynamics of Branebrutinib (BMS-986195), a Covalent, Irreversible Inhibitor of Bruton’s Tyrosine Kinase: Randomised Phase I, Placebo-Controlled Trial in Healthy Participants. Br J...
Biology

The receptor tyrosine kinase Ror is required for dendrite regeneration in <i>Drosophila</i> neurons

Newsemia
by Derek M. R. Nye, Richard M. Albertson, Alexis T. Weiner, J. Ian Hertzler, Matthew Shorey, Deborah C. I. Goberdhan, Clive Wilson, Kevin A. Janes,...
Pharma / Biotech

Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Newsemia
Related Articles Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective. Daru. 2020 Jan 03;: Authors: Pushpam D, Bakhshi S Abstract OBJECTIVE:...
Latest News

Irutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Newsemia
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. Source...
Biology

Structural basis for recognition of the tumor suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus

Newsemia
by Hye-Yeoung Yun, Min Wook Kim, Hye Seon Lee, Wantae Kim, Ji Hye Shin, Hyunmin Kim, Ho-Chul Shin, Hwangseo Park, Byung-Ha Oh, Won Kon Kim,...
Latest News

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Newsemia
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s...
Gastroenterology

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

Newsemia
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma Source link...
Latest News

FDA grants accelerated approval to oncology drug for treatment of key genetic driver of cancer

Newsemia
The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific...
Latest News

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Newsemia
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with...
Gastroenterology

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Newsemia
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy